메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Kim Dong Hyun (College of Pharmacy Chungnam National University) 이한솔 (충남대학교) Mun Yong-Hyeon (College of Pharmacy Chungnam National University) Koh SeokJin (College of Pharmacy Chungnam National University) Park Joon-Sun (College of Pharmacy Chungnam National University) Lee Sang Min (College of Pharmacy Chungnam National University) Kang Nae-Won (College of Pharmacy and Research Institute of Pharmaceutical Sciences Seoul National University) Lee Mee Yeon (College of Pharmacy and Research Institute of Pharmaceutical Sciences Seoul National University) 조정원 (충남대학교) 김대덕 (서울대학교) 이재영 (충남대학교)
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제50권 제6호
발행연도
2020.1
수록면
537 - 552 (16page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background Chondrosarcoma (CHS) is the second most common sarcoma. However, pathogenesis and etiology of this malignant tumor are still unclear. The primary treatment method for CHS is surgery, and CHS is often resistant to conventional chemotherapy. There are various types of nanoscale therapeutics, such as liposomes, micelles, polymeric nanoparticles, and protein-based nanotherapeutics, which have shown promising results in the treatment of CHSs that are not capable of being surgically removed. Area covered The genetics and molecular targets of CHS and its diagnostic features observed by various modalities are introduced. Diverse types of nanoscale therapeutics and their clinical benefits in the treatment of cancer are also described. In addition, the current application of nanotechnologies to CHS treatment is discussed with various nanoplatforms designed for CHS. Expert opinion Nanotechnology-based approaches have been investigated to overcome the chemo-resistance of CHS. In particular, for CHS patients with no surgical treatment options, nanomedicine is one of the promising strategies for cancer treatment, along with the immunotherapy that is being spotlighted nowadays. We speculate that the combination of nanoand immuno-therapeutics would be a breakthrough in unresectable CHS treatment, as can be seen in the case of nivolumab plus nanoparticle albumin-bound rapamycin that has shown excellent clinical outcomes.

목차

등록된 정보가 없습니다.

참고문헌 (100)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0